<DOC>
	<DOCNO>NCT03038048</DOCNO>
	<brief_summary>We compare patient experience standard 30 g needle small 33 g needle intravitreal injection ranabizumab aflibercept age relate macular degeneration , diabetic macular edema , retina vein occlusion .</brief_summary>
	<brief_title>30g vs 33g Needle Intravitreal Injections</brief_title>
	<detailed_description>This prospective , randomize , interventional pilot study , seek compare patient experience use 30-gauge versus 33-gauge needle bilateral same-day intravitreal injection ranibizumab aflibercept treatment wet age-related macular degeneration ( AMD ) , diabetic macular edema ( DME ) , macular edema associate retinal vein occlusion ( RVO ) . The null hypothesis difference patient discomfort pain 30-gauge needle compare 33-gauge needle .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients undergoing bilateral , sameday , intravitreal injection either ranibizumab oraflibercept diagnosis wet AMD , DME , RVOassociated macular edema 1 ) Patients receive Betadine ophthalmic solution prior intravitreal injection due document allergy 2 ) Patients receive intravitreal bevacizumab ( medication iscompounded prefilled 1mL tuberculin syrinx ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>